KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash from Operations: 2017-2025

Historic Cash from Operations for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to -$11.8 million.

  • Twist Bioscience's Cash from Operations rose 22.89% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.6 million, marking a year-over-year increase of 25.69%. This contributed to the annual value of -$47.6 million for FY2025, which is 25.69% up from last year.
  • According to the latest figures from Q3 2025, Twist Bioscience's Cash from Operations is -$11.8 million, which was down 743.86% from -$1.4 million recorded in Q2 2025.
  • Twist Bioscience's 5-year Cash from Operations high stood at -$1.3 million for Q3 2022, and its period low was -$54.1 million during Q4 2022.
  • For the 3-year period, Twist Bioscience's Cash from Operations averaged around -$18.2 million, with its median value being -$19.4 million (2024).
  • Per our database at Business Quant, Twist Bioscience's Cash from Operations surged by 96.36% in 2022 and then slumped by 1,534.10% in 2023.
  • Quarterly analysis of 5 years shows Twist Bioscience's Cash from Operations stood at -$46.7 million in 2021, then dropped by 15.90% to -$54.1 million in 2022, then skyrocketed by 57.51% to -$23.0 million in 2023, then grew by 6.73% to -$21.4 million in 2024, then rose by 22.89% to -$11.8 million in 2025.
  • Its Cash from Operations stands at -$11.8 million for Q3 2025, versus -$1.4 million for Q2 2025 and -$13.0 million for Q1 2025.